



ASX Announcement

August 30, 2021

CHIMERIC APPOINTS JENNIFER CHOW AS CEO & MD

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce the appointment of current Chief Operating Officer, Jennifer Chow, as Chief Executive Officer and Managing Director.

Ms Chow has been Chief Operating Officer of Chimeric since November 2020. Prior to joining Chimeric, Ms Chow was Head of Global Marketing, Analytics and Commercial Operations at leading global CAR T company Kite Pharmaceuticals (acquired by Gilead Sciences in 2017 for US\$12 billion). Ms Chow was responsible for assessing and prioritizing research and external assets for development, ensuring optimal clinical development of the Kite pipeline for global commercialisation.

Ms Chow has more than 20 years of commercial strategy and marketing experience focused on cellular therapy, hematology and oncology. She was previously Global Cell Therapy Commercial Lead at Celgene Corporation and was responsible for designing and developing the global CAR T commercial strategy and operating model. Ms Chow was also formerly at Roche, Nycomed/Takeda and Schering Canada.

“We are delighted to announce the appointment of Jennifer as MD & CEO. During her time with Chimeric thus far as COO, Jennifer has demonstrated outstanding dedication and leadership while importantly proving to be exceedingly knowledgeable in the field of cell therapy,” said Paul Hopper, Executive Chairman, Chimeric Therapeutics.

“The team we’ve been able to assemble at Chimeric brings deep scientific & commercial cell therapy expertise to the business and gives us great confidence moving forward under Jenn’s leadership.”

For the purpose of ASX Listing Rule 3.16.4, a summary of the material terms of Ms Chow’s employment agreement is set out in appendix 1.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.



To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric Therapeutics is currently in a phase 1 clinical trial for its CHM 1101 asset (CLTX CAR T). CLTX CAR T is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM) developed by scientists at the City of Hope Medical Centre in California.

Chimeric also recently announced the expansion of their pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CAR T directed at CDH17. CHM 2101 is currently in preclinical development with a planned move to the clinic in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Paul Hopper
Executive Chairman
Chimeric Therapeutics
P: +61 (0) 3 9824 5254
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 1: Summary of material terms of executive employment contract

Commencement Date	Remuneration effective 1 July 2021
Term	No fixed term. Employment will continue until terminated by either party, as summarised below.
Total Fixed Remuneration	US\$ 550,000 reviewed annually, plus an industry standard health benefits package
Incentive Remuneration	<p>Subject to shareholder approval:</p> <ul style="list-style-type: none"> • That for FY2022 incentive remuneration Ms Chow will be issued with options subject to performance milestones & • Be issued with 2 million options exercisable at \$0.34 per option, vesting over three years with an expiry date of 5 years from issue date. <p>The terms of this scheme are set out in the Omnibus Incentive Plan released to the ASX on 18 January 2021.</p>
Agreement and termination	Ms Chow's employment agreement contains standard terms and conditions for an agreement of this nature, including confidentiality, restraint on competition and retention of intellectual property provisions.
Prior commitments	<p>As noted in the Prospectus published on 18 January 2021, and prior to Ms Chow being appointed as CEO & MD:</p> <ul style="list-style-type: none"> • Ms Chow is entitled to received US\$ 1.2 million payable 50% in cash and 50% in equity for forfeiture of her Long-Term Share Incentive Payment from her previous employer. This is payable one third annually starting 1 December 2021.